RU2020111574A - Высококонцентрированные, маловязкие препараты ингибирующих masp-2 антител, наборы и способы лечения субъектов, страдающих атипическим гемолитическим синдромом - Google Patents

Высококонцентрированные, маловязкие препараты ингибирующих masp-2 антител, наборы и способы лечения субъектов, страдающих атипическим гемолитическим синдромом Download PDF

Info

Publication number
RU2020111574A
RU2020111574A RU2020111574A RU2020111574A RU2020111574A RU 2020111574 A RU2020111574 A RU 2020111574A RU 2020111574 A RU2020111574 A RU 2020111574A RU 2020111574 A RU2020111574 A RU 2020111574A RU 2020111574 A RU2020111574 A RU 2020111574A
Authority
RU
Russia
Prior art keywords
antibody
weeks
masp
period
months
Prior art date
Application number
RU2020111574A
Other languages
English (en)
Russian (ru)
Other versions
RU2020111574A3 (enExample
Inventor
Грегори А. ДЕМОПУЛОС
Кеннет М. ФЕРГЮСОН
Уилльям Джозеф ЛАМБЕРТ
Джон Стивен УАЙТЕЙКЕР
Original Assignee
Омерос Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Омерос Корпорейшн filed Critical Омерос Корпорейшн
Publication of RU2020111574A publication Critical patent/RU2020111574A/ru
Publication of RU2020111574A3 publication Critical patent/RU2020111574A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
RU2020111574A 2017-08-25 2018-08-21 Высококонцентрированные, маловязкие препараты ингибирующих masp-2 антител, наборы и способы лечения субъектов, страдающих атипическим гемолитическим синдромом RU2020111574A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762550328P 2017-08-25 2017-08-25
US62/550,328 2017-08-25
PCT/US2018/047255 WO2019040453A1 (en) 2017-08-25 2018-08-21 HIGHLY CONCENTRATED MASP-2 INHIBITOR ANTIBODY FORMULATIONS WITH LOW VISCOSITY, KITS AND METHODS FOR TREATING SUBJECTS SUFFERING FROM ATYPICAL HEMOLYTIC SYNDROME

Publications (2)

Publication Number Publication Date
RU2020111574A true RU2020111574A (ru) 2021-09-27
RU2020111574A3 RU2020111574A3 (enExample) 2021-11-17

Family

ID=65436837

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2020111574A RU2020111574A (ru) 2017-08-25 2018-08-21 Высококонцентрированные, маловязкие препараты ингибирующих masp-2 антител, наборы и способы лечения субъектов, страдающих атипическим гемолитическим синдромом

Country Status (15)

Country Link
US (2) US20190062455A1 (enExample)
EP (1) EP3672994A4 (enExample)
JP (1) JP2020531523A (enExample)
KR (1) KR20200037863A (enExample)
CN (1) CN111278863A (enExample)
AU (1) AU2018322032B2 (enExample)
BR (1) BR112020003632A2 (enExample)
CA (1) CA3072913A1 (enExample)
CL (1) CL2020000397A1 (enExample)
IL (1) IL272673B2 (enExample)
MA (1) MA49960A (enExample)
MX (1) MX2020002077A (enExample)
RU (1) RU2020111574A (enExample)
TW (1) TW201925224A (enExample)
WO (1) WO2019040453A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114641270A (zh) * 2019-11-15 2022-06-17 豪夫迈·罗氏有限公司 防止水性蛋白质溶液中可见颗粒的形成
TW202135860A (zh) * 2019-12-10 2021-10-01 美商再生元醫藥公司 含有抗ｃｄ２０ｘ抗ｃｄ３雙特異性抗體之穩定調配物
IL300245A (en) * 2020-07-31 2023-03-01 Alamab Therapeutics Inc Anti-connexin antibody formulations
EP4489782A4 (en) * 2022-03-10 2026-03-25 Omeros Corp MASP-2 and MASP-3 inhibitors, and associated compositions and methods for the treatment of sickle cell disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY34054A (es) * 2011-05-02 2012-11-30 Millennium Pharm Inc FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7
HUE049154T2 (hu) * 2011-05-04 2020-09-28 Omeros Corp Készítmények a MASP-2-függõ komplement-aktiválás gátlására
PT2861246T (pt) * 2012-06-18 2021-04-05 Univ Leicester Composições e métodos para inibir masp-1 e/ou masp-2 e/ou masp-3 para o tratamento de várias doenças e perturbações
RS61351B1 (sr) * 2013-10-17 2021-02-26 Omeros Corp Postupci za lečenje stanja udruženih sa aktivacijom komplementa zavisnom od masp-2
US20160168237A1 (en) * 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. Method for treating a complement mediated disorder caused by an infectious agent in a patient
CN117398458A (zh) * 2015-11-09 2024-01-16 奥默罗斯公司 用于治疗与masp-2依赖性补体活化相关的病况的方法
JOP20170170B1 (ar) * 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق

Also Published As

Publication number Publication date
AU2018322032B2 (en) 2025-04-17
IL272673B2 (en) 2024-10-01
KR20200037863A (ko) 2020-04-09
RU2020111574A3 (enExample) 2021-11-17
MA49960A (fr) 2021-06-02
IL272673B1 (en) 2024-06-01
CL2020000397A1 (es) 2020-07-10
CA3072913A1 (en) 2019-02-28
JP2020531523A (ja) 2020-11-05
AU2018322032A1 (en) 2020-03-12
MX2020002077A (es) 2020-03-24
US20240247078A1 (en) 2024-07-25
BR112020003632A2 (pt) 2020-10-27
US20190062455A1 (en) 2019-02-28
WO2019040453A1 (en) 2019-02-28
CN111278863A (zh) 2020-06-12
TW201925224A (zh) 2019-07-01
IL272673A (en) 2020-03-31
EP3672994A4 (en) 2021-06-02
EP3672994A1 (en) 2020-07-01

Similar Documents

Publication Publication Date Title
JP2022532927A5 (enExample)
AR109494A1 (es) Formulaciones de anticuerpos inhibidores de masp-2 de baja viscosidad y altamente concentradas, kits, y métodos
JP2020203889A (ja) 抗体製剤
RU2006120950A (ru) Антитело к cd40: препарат и способы
RU2013125775A (ru) Способы лечения ревматоидного артрита с применением антагонистов il-17
US20150071936A1 (en) Pharmaceutical formulations of tnf-alpha antibodies
JP2017160208A5 (enExample)
JP2013543501A5 (enExample)
JP2023527563A5 (enExample)
IL274846B2 (en) Formulation for anti-alpha 4 antibody in cell 7
RU2013148537A (ru) Стабильные составы антител против рецептора программируемой смерти pd-1 человека и относящиеся к ним способы лечения
RU2011108025A (ru) Стабильный жидкий препарат антитела
RU2016103079A (ru) Составы антител и способы
CA2794929A1 (en) Concentrated protein formulations and uses thereof
RU2010142309A (ru) Способы лечения псориаза
RU2014101207A (ru) Новые показания к применению при лечении антителами против il-1-бета
RU2015104001A (ru) Комбинированная терапия для лечения глиобластомы
JP2024515968A5 (enExample)
RU2012108108A (ru) Концентрированные полипептидные лекарственные формы с пониженной вязкостью
JP2024544523A5 (enExample)
JP2019521156A5 (enExample)
JP2019532970A5 (enExample)
JP2019519584A5 (enExample)
JP2023507795A5 (enExample)
JP2020531523A5 (enExample)